Sarepta Therapeutics (SRPT) Current Leases (2022 - 2023)
Sarepta Therapeutics' (SRPT) quarterly Current Leases came in at $17.8 million in Q4 2023, up 15.21% year-on-year from $15.5 million in Q4 2022, and up 15.21% quarter-over-quarter from $15.5 million in Q4 2022.
Sarepta Therapeutics (SRPT) Current Leases (2022 - 2023) Analysis & Trends
Sarepta Therapeutics' Current Leases history runs 2 years deep, the most recent figure standing at $17.8 million for Q4 2023.
- On a quarterly basis, Current Leases rose 15.21% year-over-year to $17.8 million in Q4 2023; TTM through Dec 2023 was $17.8 million, a 15.21% increase from a year earlier, with the FY2023 full-year figure at $17.8 million, up 15.21% from the prior year.
- Current Leases improved to $17.8 million in Q4 2023 per SRPT's latest filing, from $15.5 million in the prior quarter.
- Across five years, Current Leases topped out at $17.8 million in Q4 2023 and bottomed at $15.5 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 531,233.95 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 20.58 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 872,589.03 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 720.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 11.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.61 Mn |
| 10 | Sarepta Therapeutics | 1.69 Bn | 1.28 Bn | 622.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 17.85 Mn |
| Dec 31, 2022 | 15.49 Mn |